Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Strong 2Q And Fresh UK Investment Signal Few Brexit Blues at GSK

Executive Summary

GlaxoSmithKline reported a strong second quarter and along with its core EPS guidance upgrade, this adds momentum to its post-Brexit vote boost.


Related Content

3Q Pharma Results Preview: Novartis, Merck, Lilly, Bayer, GSK, Bristol, Amgen, Sanofi
UK Pharma's 'Brexit Playbook' Might Envision New Regulator Roles
GSK And Google To Invest £540m In UK-Headquartered Bioelectronics JV
GSK Foresees Return To Emerging Markets Growth
GSK's Vaccines Chief Slaoui To Follow Witty Out The Door
GSK Ups Ante In Triple COPD Therapy Race But Payers Wary
What’s On CEO Andrew Witty’s To-Do List Before Exiting GSK